Cost cuts to the rescue for Teva, so far

Cost cuts to the rescue for Teva, so far

Source: 
BioPharma Dive
snippet: 

Teva on Thursday reported first quarter sales fell 19% versus the same period in 2018, as its top-seller Copaxone suffers from generic challenges and the company's own copycat business faces continued pricing pressure.